Latest Cancer stem cell Stories
SYDNEY, Aug. 13, 2014 /PRNewswire/ -- Australia-US biotechnology company, Novogen Ltd.
The Adult Stem Cell Technology Center, LLC in Boston Massachusetts has more adult stem cell intellectual property than it requires for its own current business development plans.
Phase I studies start in 2015 NEW HAVEN, Conn., July 25, 2014 /PRNewswire/ -- Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd.
Many current regenerative medicine trials are based on heterologous stem cell transplantation, in which stem cells multiplied from one type of organ or tissue are transferred to treat diseases,
Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma.
A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy.
A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice.
Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 BOSTON, June 17, 2014 /PRNewswire/ -- Australian oncology drug development company Novogen
CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- Boston Biomedical, a company focused on the research and development of novel cancer therapeutics targeting cancer stem cells (CSC), today provided